Ashley Bartz
Payments from drug & device makers
Across 271 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$427
- GSK$403
- Lilly USA, LLC$400
- AstraZeneca$302
- Amgen$241
- AbbVie$239
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,298100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $427 |
| GSK | 33 | $403 |
| Lilly USA, LLC | 31 | $400 |
| AstraZeneca | 19 | $302 |
| Amgen | 14 | $241 |
| AbbVie | 12 | $239 |
| Gilead | 11 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $223 |
| Pfizer | 11 | $191 |
| Johnson & Johnson | 12 | $178 |
| Esperion Therapeutics, Inc. | 7 | $175 |
| Boehringer Ingelheim | 10 | $167 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $162 |
| Biohaven Pharmaceuticals, Inc. | 8 | $133 |
| Merck | 8 | $118 |
| Kowa Pharmaceuticals America, Inc. | 5 | $115 |
| Daiichi Sankyo Inc. | 6 | $97 |
| Grifols USA, LLC | 5 | $83 |
| Bayer | 4 | $81 |
| Novartis | 3 | $51 |
| Currax Pharmaceuticals LLC | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 4 | $48 |
| Abbott | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $36 |
| Exact Sciences | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,298 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 62 | $75,165 |
| TrulicityDulaglutide | 34 | $71,571 |
| EliquisApixaban | 53 | $68,451 |
| OzempicSemaglutide | 41 | $52,006 |
| JardianceEmpagliflozin | 33 | $46,959 |
| MyrbetriqMirabegron | 40 | $35,547 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $34,830 |
| MounjaroTirzepatide | 20 | $21,126 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $19,467 |
| FarxigaDapagliflozin Propanediol | 24 | $19,188 |
| Repatha SureclickEvolocumab | 24 | $13,019 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,872 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $4,207 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $3,946 |
| Rosuvastatin Calcium | 208 | $3,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $400 | $92,69754 claims |
| Johnson & JohnsonXarelto | $178 | $75,16562 claims |
| PfizerEliquis | $191 | $68,45153 claims |
| Novo NordiskOzempic | $427 | $52,00641 claims |
| Boehringer IngelheimJardiance | $167 | $46,95933 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $302 | $43,52759 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $403 | $38,77652 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $35,54740 claims |
| Esperion Therapeutics, Inc.Nexlizet | $175 | $4,20711 claims |
| AbbVieSynthroid | $239 | $2,21831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.
Other medical in Olean
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.